Immunic Inc (NASDAQ:IMUX) CEO Daniel Vitt speaks to Proactive's Thomas Warner about how the clinical-stage biopharmaceutical business is positioned heading into 2023.
Vitt reveals the "unique approach" that he believes Immunic is taking in the sector and looks ahead to what investors can expect from the business in the coming months.